Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Flu Vaccine Schedule Expansion Could Cost Public Sector $60 Mil. Annually

Executive Summary

Expanding influenza vaccination recommendations to include infants between six and 23 months and children who are household contacts of high-risk groups could increase costs to the public sector by $59.6 mil. annually
Advertisement

Related Content

Pediatric flu vaccine data
Pediatric flu vaccine data
Aventis Fluzone pediatric
Aventis Fluzone pediatric
FDA Evaluating Vaccine GMP Requirements To Assess Impact on Supply
Vaccine GMP Reevaluation Needed, NVAC Draft Report On Shortages Says
Wyeth Prevnar Capacity Expansion Planned For 2003; Shortage Until Then
Wyeth Prevnar Capacity Expansion Planned For 2003; Shortage Until Then
Thimerosal-Free Flu Vaccine Design Being Discussed By FDA, Manufacturers
Advertisement
UsernamePublicRestriction

Register

PS040117

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel